Recent content by Justin De Moss

My pleasure. At HEI we try to be different than everyone else. I've tried to make it more personal by responding to emails, texts, forums, etc. I tried not to use canned or stock answers/emails. I tried to post on here as much as I could. I have had a lot of joy these last 3+ years and will...

A huge thank you to everyone on here. I hope you all will still consider supporting HEI's research efforts. Right now, any new donor has their gift matched 100% by the JASCO Giving Hope Foundation here in OKC. Anyone who has given in the last two years can have their gift matched if they give...

This is a report from our COO of HEI and our research team on the milestones this year with our proof-of-concept study: We were able to develop a unique model of noise-induced neurodegeneration that does not result in permanent hearing loss but does evoke a chronic tinnitus percept. This is...

Keep in mind this was an article written by a reporter. They don't always get the facts straight. Before we got connected to Dr. Kesari were already working on funding this POC study because we already had pre-clinical data that indicated the pill's efficacy on tinnitus. Dr. Kesari was...

To speed things up takes money. We are a non-profit that relies on government funding and private donations. The two-year proof-of-concept study has several objectives. I will post what milestones we have accomplished in another post. To help you better understand what is happening, imagine...

Hi! I was in the room training the lady you spoke to. Let me clear up a few things that got misunderstood. NHPN-1010 is in a proof-of-concept study (2 years) before tinnitus will be considered for a Phase II study for the clinical indication of tinnitus. That doesn't mean Oblato can't move...

The real term is expanded use. Read more here: https://www.fda.gov/news-events/public-health-focus/expanded-access Read more here: https://www.fda.gov/news-events/public-health-focus/expanded-access

Yes, the cause of one condition can be the cause of a second condition. So, the mechanism of how the drug works can have multiple uses. Also, the drug works in multiple ways. We have data that indicates it works for SNHL, ototoxicity, and tinnitus. We believe it may be helpful for hyperacusis...

Or blast-induced. There are probably several "causes" of tinnitus. We are going after the most prevalent one, at least what is thought to be the most prevalent cause.

Incorrect, the article says patient, singular. Not plural. We also are unsure how accurate this article is and are inquiring. Sometimes we are the last to know ;)

We have data on the pill's efficacy in pre-clinical trials for SNHL, ototoxicity, and tinnitus. We believe it might also be helpful with hyperacusis and Meniere's disease. The pill helps absorb toxins/reduce inflammation and regenerate meaningful nerve connections between the cochlea and the...

We don't know yet. The questions you are asking are generally found when dosing is determined, which is Phase II and III clinical trials. Our estimation is that it would be a one-course treatment. That might be one pill or a month of pills. Our research suggests that once the nerve endings or...

Expanded Use is typically done on a case-by-case basis. Reading the article, it talks about "a chronic tinnitus patient." NOT patients, plural. To be clear ;)

Hi everyone, @Markku asked me to jump on real quick and give everyone an update on the news article from koreamed.com. I read through some of the comments and questions here. I will do my best today to answer them individually - but there are some "repeats" so be sure to check out all the...

We didn't choose cochlear implant trauma. Which indication they (the biotech firm) choose is still in the air right now. The delays in clinical research has to do with the pandemic, and less with what indication is chosen.